Marpai (MRAI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for August 27, 2025, to elect six directors, ratify the auditor, and approve a charter amendment for preferred stock authorization.
Record date for voting is June 30, 2025; shareholders can vote by mail, online, or in person.
Board unanimously recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposals include electing six directors, ratifying UHY LLP as auditor for 2025, and amending the certificate of incorporation to authorize 2,000,000 shares of blank-check preferred stock.
Board recommends a vote FOR all proposals.
Shareholders may submit proposals for the 2026 annual meeting by the specified deadline.
Board of directors and corporate governance
Board consists of a mix of executive and independent directors; four directors meet Nasdaq independence standards.
Audit and compensation committees are established; audit committee chaired by Sagiv Shiv, compensation committee chaired by Colleen DiClaudio.
No standing nominating committee; independent directors recommend nominees.
Board and committees oversee risk management, compliance, and executive compensation.
Code of Ethics and insider trading policy in place; stockholder communications encouraged.
Latest events from Marpai
- Q2 2024 saw a 28% revenue drop, $13M net loss, and a $7.6M impairment charge.MRAI
Q2 20242 Feb 2026 - Q3 2024 losses narrowed as cost cuts offset revenue decline, but liquidity risks remain.MRAI
Q3 202415 Jan 2026 - Losses narrowed in 2024; new PBM products and partnerships target 2025 profitability.MRAI
Q4 202426 Dec 2025 - Board seeks approval for director elections, auditor ratification, and preferred stock authorization.MRAI
Proxy Filing2 Dec 2025 - Facing ongoing losses and liquidity risks, the company relies on new capital to sustain operations.MRAI
Registration Filing29 Nov 2025 - Q2 2025 saw revenue drop but major cost cuts, with profitability targeted for early 2026.MRAI
Q2 202523 Nov 2025 - Revenue fell 27% to $5.4M; net loss improved, but liquidity and funding risks remain.MRAI
Q1 202519 Nov 2025 - Q3 2025 revenue fell 42%, but cost cuts and new funding drive a turnaround amid liquidity risks.MRAI
Q3 202517 Nov 2025